ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
MRAS: Master Regulator Analysis of Alternative Splicing.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unraveling the FGFR-RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose.Acta pharmaceutica Sinica. B · 2026Review
- Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.MedComm · 2025Review
- MRAS: Master Regulator Analysis of Alternative Splicing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As a molecular feature that characterizes most tumor types, cancer-associated splicing dysregulation largely arises from recurrent genetic mutations and altered expression of trans-acting splicing factors. Although splicing factor mutations occur less frequently in solid tumors, splicing disorders are pervasive and proven to promote tumorigenesis. However, it still lacks an efficient way to identify the key splicing factors at the top regulatory hierarchy whose abnormal expressions induce such splicing disorders and drive phenotypic variability. Here, MRAS (Master Regulator analysis of Alternative Splicing) is introduced, a computational method designed to pinpoint the pivotal splicing factors that play a central role in shaping splicing regulatory networks and influencing cellular processes. MRAS is demonstrated its power by identifying master splicing regulators associated with various disease phenotypes, including tumor initiation, progression, metastasis, and treatment resistance. Moreover, by applying MRAS to single-cell RNA-seq data, crucial regulatory relationships that govern cell-type specific splicing programs have been uncovered. Overall, MRAS presented as an accurate and versatile approach to unraveling the underlying mechanism of splicing regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.